source
- Lilly's triple-agonist retatrutide drives up to 18.8% weight loss, over half of patients fall below obesity thresholdAt the EASD Annual Meeting in Milan, Eli Lilly presented data on its triple‑agonist retatrutide. The trial involved participants with obesity and type 2 diabetes and showed weight reductions of up…
- Zealand and Roche's amylin analog shows modest weight loss at middle dose, lagging behind Lilly's in Phase 2 trialZealand and Roche reported new data from their Phase 2 obesity trial of an amylin analog at a recent conference. The earlier topline results in March had been viewed as disappointing. The updated…Endpoints · 20d agoNegative readoutNegative